Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Guana

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Journal of Dermatologic Surgery and Oncology|April 1, 1994
Stump the expertsA Guana, R V Kolbusz, L H Goldberg
International Journal of Dermatology|August 1, 1994
Treatment of a recurrent keratoacanthoma with oral isotretinoinW Y Wong, R V Kolbusz, L H Goldberg, et al.
The British Journal of Dermatology|June 6, 2017
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension studyR Bissonnette, T Luger, D Thaçi, et al.
The British Journal of Dermatology|January 23, 2018
Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysisD E Stull, C E M Griffiths, I Gilloteau, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 12, 2017
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR studyA Blauvelt, K Reich, S Mehlis, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Journal of Dermatologic Surgery and Oncology|April 1, 1994
Stump the expertsA Guana, R V Kolbusz, L H Goldberg
International Journal of Dermatology|August 1, 1994
Treatment of a recurrent keratoacanthoma with oral isotretinoinW Y Wong, R V Kolbusz, L H Goldberg, et al.
The British Journal of Dermatology|June 6, 2017
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension studyR Bissonnette, T Luger, D Thaçi, et al.
The British Journal of Dermatology|January 23, 2018
Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysisD E Stull, C E M Griffiths, I Gilloteau, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 12, 2017
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR studyA Blauvelt, K Reich, S Mehlis, et al.
Pageof 1